Updated:
Daré Bioscience
Daré Bioscience is a publicly traded biotech firm led by Sabrina Martucci Johnson, focusing on women's health therapeutics.
Daré Bioscience
Sabrina Martucci Johnson founded Daré Bioscience after becoming frustrated with the lack of industry commitment to women's health. The firm is headquartered in San Diego and operates as a publicly traded biotech company, listed on the NASDAQ under the ticker DARE. Its mission is to bring evidence-based treatments to conditions like contraception, menopause, and vaginal health that the medical establishment has historically underfunded. The company's strategy spans several therapeutic areas via its product lines: DARE to PLAY (a topical sildenafil cream for female arousal), DARE to RESTORE (a vaginal probiotic), and DARE to RECLAIM, DARE to SUPPORT, DARE to PLAN, and DARE to FIGHT covering menopause support, contraception, and vaginal health. Its most advanced candidate is Ovaprene, a hormone-free contraceptive that posted positive interim Phase 3 results in May 2026 (per the firm, May 2026). Daré reports its pipeline is based on randomized, controlled clinical trials and peer-reviewed publications. The firm operates as a public company with 58 listed professionals, including a Chief Scientific Officer, medical directors, and operations leads. It has disclosed spending on women's health research and product development, though total deployment figures are not publicly available. A recent operational event: May 2026, reported positive interim Phase 3 results for Ovaprene, a novel hormone-free contraceptive (per the firm, May 2026). Daré Bioscience is structurally distinct from a typical venture-backed biotech—it is publicly traded, not family-office funded, and its mission-driven mandate focuses exclusively on women's health. The company's regulatory posture as a NASDAQ-listed entity compels public financial disclosures, but it does not operate as a family office or investment vehicle.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
Sabrina Martucci Johnson
Chief Executive Officer & President
David Friend, PhD
Chief Scientific Officer
MarDee Haring-Layton
Chief Accounting Officer
Jessica Hatheway
Vice President, Clinical Operations
Annie Thurman, MD, FACOG
Medical Director
Mark Walters
Vice President, Operations
Robert Charboneau
Vice President, Manufacturing & Supply Chain
Jennifer Kiang
Vice President, Corporate Affairs and Development
Christine Mauck M.D.
Medical Director
Nicolas Pacelli
Vice President, Alliance Management and Business Development
Elizabeth Proos
Vice President, Product Development
William H. Rastetter, PhD
Chairman of the Board
Jessica Grossman, MD
Board Member
Susan L. Kelley, MD
Board Member
Gregory W. Matz, CPA
Board Member
Robin Steele, JD, LLM
Board Member
Sector focus
Frequently asked questions
Who runs investment decisions at Daré Bioscience?
As a publicly traded company, investment decisions are overseen by its board of directors and executive management, including CEO Sabrina Martucci Johnson. The firm does not operate as a family office or investment vehicle, so capital allocation is focused on R&D and clinical trials for women's health products.
Is Daré Bioscience a family office?
No. Daré Bioscience is a publicly traded biotech company listed on the NASDAQ. It does not manage capital for any family or foundation and is not structured as a family office. Its revenue comes from product sales and public equity markets, not family office allocations.
Does Daré Bioscience accept external investment or partnerships?
Daré appears to fund its operations through public equity markets and potentially partnerships, as indicated by its status as a publicly traded company. It does not disclose a family office or venture capital fund structure. The firm has executed at least one partnership—it has a product candidate for female arousal cream (DARE to PLAY) that is available for pre-fulfillment prescriptions.
What is Daré Bioscience's most advanced product candidate?
The most advanced candidate is Ovaprene, a hormone-free contraceptive that posted positive interim Phase 3 results in May 2026 (per the firm, May 2026). The company also has one FDA-approved product and multiple other candidates in clinical trials covering contraception, menopause, and vaginal health.
What investment stages does Daré Bioscience target?
Daré is a clinical-stage biotech, meaning it targets early- to mid-stage development of therapeutics. It conducts end-to-end clinical development, from preclinical research through FDA submission. The firm does not invest in external companies or funds.
Where does the underlying wealth for Daré Bioscience come from?
Daré is a publicly traded company, not a family office. Its capital comes from public equity markets (NASDAQ: DARE), not from a single family or wealthy individual. The firm's founder, Sabrina Martucci Johnson, did not disclose personal wealth origin in relation to the company.
What is Daré Bioscience's known posture on co-investments alongside external GPs?
Daré does not participate in co-investments with GPs. As a publicly traded biotech, it focuses on internal R&D and clinical development rather than acting as an investment partner. If you are seeking a family office with co-investment capabilities, Daré is not a relevant firm.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: